4 assets in Spindle Cell Rhabdomyosarcoma

Therapeutic assets addressing Spindle Cell Rhabdomyosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Spindle Cell Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Dactinomycin Spindle Cell Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vincristine Sulfate Spindle Cell Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vinorelbine Ditartrate Spindle Cell Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)